69C Stock Chart & Stats
€1.20
-€0.34(-22.08%)
At close: 4:00 PM EDT
€1.20
-€0.34(-22.08%)
Day’s Range― - ―
52-Week Range€0.93 - €37.00
Previous CloseN/A
Volume0.00
Average Volume (3M)155.00
Market Cap
€14.40M
Enterprise Value€5.03
Total Cash (Recent Filing)€24.98M
Total Debt (Recent Filing)€174.00K
Price to Earnings (P/E)―
Beta-0.48
Next Earnings
Aug 14, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding9,381,344
10 Day Avg. Volume0
30 Day Avg. Volume155
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.96Price Target Upside646.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Validated TTI-109 PK And Target EngagementPhase 1 pharmacokinetic and pharmacodynamic validation materially de-risks Tvardi's prodrug strategy. Demonstrated conversion, dose-proportional exposure and up to 60% reductions in STAT3-driven cells, plus improved GI tolerability, strengthen the scientific rationale and support broader Phase 2 development and partner interest over the coming quarters.
Clear Strategic Focus On Ulcerative ColitisDesignating ulcerative colitis as the lead indication provides a defined clinical and commercial pathway into a large, underserved GI market. This focus concentrates resources, clarifies endpoints for development and KOL engagement, and makes the program more investable to potential partners, improving chances of sustained clinical prioritization and external support.
Low Leverage And Improved Equity BaseVery low reported debt and a recently positive equity position reduce immediate leverage risk and preserve flexibility. An improved balance sheet from financing activity gives the company more negotiating power with partners and lenders, helping to fund clinical milestones without onerous debt service that could impair long-term R&D execution.
Bears Say
No Current Revenue And Persistent LossesThe company currently reports no commercial revenue and sustained negative earnings, meaning it lacks internal cash generation to fund development. Over multiple quarters this necessitates external funding to advance trials and creates execution risk if capital access tightens, limiting self-sufficiency in the medium term.
Heavy Cash Burn And Negative Operating/free Cash FlowSustained cash outflows of roughly $23–25M annually indicate significant runway pressure relative to a non-revenue profile. Persistent negative operating and free cash flow raises the probability of future equity raises or partnership dependence, potentially diluting shareholders and forcing prioritization of programs over optimal scientific timelines.
Progress Contingent On IND Clearance And New FundingPlanned Phase 2 and ulcerative colitis studies require investigational new drug clearance and fresh capital. These binary regulatory and financing milestones introduce execution risk and potential delays; failure or slippage could materially defer development, erode partner interest and compress the company's ability to capitalize on Phase 1 momentum.
Tvardi Therapeutics News
69C FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was €0.93 and its highest was €37.00 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is €14.40M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Aug 14, 2026 which is today.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.61.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in DE:69C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
69C Stock 12 Month Forecast
Average Price Target
€8.96
▲(646.52% Upside)
Technical Analysis
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―